The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 May 2026•

1 min read

Alkermes Shifts Focus to Sleep Medicine Amid Strong Sales Growth and Positive 2026 Outlook

Key Facts

1Alkermes proprietary product sales rose to $338.1M in Q1 2026.

2LUMRYZ contributed $39.5M to revenue following the Avadel acquisition.

3Management projects 2026 revenues between $1.73B and $1.84B.

Alkermes has reported robust financial results for the first quarter of 2026, signaling a successful strategic pivot toward neuroscience and sleep medicine. Proprietary product sales climbed to $338.1 million during the quarter, driven by strong performance across its portfolio. Notably, the drug LUMRYZ contributed $39.5 million to total revenue following the company's acquisition of Avadel. Management has issued positive forward guidance, projecting full-year 2026 revenues to fall between $1.73 billion and $1.84 billion. This growth in revenue and EBITDA highlights the effective integration of recent mergers and acquisitions. Overall, the results underscore Alkermes' ability to capture market share in the high-growth sleep medicine sector while maintaining a solid financial trajectory.